Literature DB >> 29152546

Advances in Behavioral Laboratory Methods that Inform Tobacco Regulatory Science: A TCORS Working Group Special Issue.

M Jerry Wright1, Gerald Valentine2.   

Abstract

OBJECTIVE: The 2009 Family Smoking Prevention and Tobacco Control Act (TCA) created unprecented enabling conditions for establishing national regulatory policy that reduces the burden of public health and societal problems associated with tobacco product use. The Center for Tobacco Products (CTP), created by the FDA to implement the TCA, developed a first-of-its-kind FDA/National Institutes of Health (NIH) collaborative program to fund Tobacco Centers of Regulatory Science (TCORS).
METHODS: To assist the TCORS with addressing research priorites, working groups (WGs) comprised of FDA-CTP liasions and TCORS investigators were formed. Under the direction of the Center for Evaluation and Coordination of Trainin and Research (CECTR), the TCORS WGs seek to develop tangible work products in their respective areas of focus.
RESULTS: The focus of the behavioral pharmacology WG evolved from publishing a narrow paper on behavioral methods in electronic cigarette research to a collection of papers on advances in behavioral laboratory methods that may inform tobacco regulatory science.
CONCLUSION: This Special Issue contains articles that address all of the CTP research priorities and demonstrates how advances in behavioral laboratory methods made by TCORS investigators can inform FDA efforst to regulate tobacco products.

Entities:  

Year:  2016        PMID: 29152546      PMCID: PMC5693251          DOI: 10.18001/TRS.2.4.1

Source DB:  PubMed          Journal:  Tob Regul Sci        ISSN: 2333-9748


  73 in total

Review 1.  Cue dependency of nicotine self-administration and smoking.

Authors:  A R Caggiula; E C Donny; A R White; N Chaudhri; S Booth; M A Gharib; A Hoffman; K A Perkins; A F Sved
Journal:  Pharmacol Biochem Behav       Date:  2001-12       Impact factor: 3.533

2.  Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors.

Authors:  L M Marubio; A M Gardier; S Durier; D David; R Klink; M M Arroyo-Jimenez; J M McIntosh; F Rossi; N Champtiaux; M Zoli; J-P Changeux
Journal:  Eur J Neurosci       Date:  2003-04       Impact factor: 3.386

Review 3.  Cellular and synaptic mechanisms of nicotine addiction.

Authors:  Huibert D Mansvelder; Daniel S McGehee
Journal:  J Neurobiol       Date:  2002-12

4.  Age-dependent effects of nicotine on locomotor activity and conditioned place preference in rats.

Authors:  James D Belluzzi; Alex G Lee; Heather S Oliff; Frances M Leslie
Journal:  Psychopharmacology (Berl)       Date:  2004-01-22       Impact factor: 4.530

5.  Progressive ratio as a measure of reward strength.

Authors:  W HODOS
Journal:  Science       Date:  1961-09-29       Impact factor: 47.728

6.  Mentholated cigarette smoking inhibits nicotine metabolism.

Authors:  Neal L Benowitz; Brenda Herrera; Peyton Jacob
Journal:  J Pharmacol Exp Ther       Date:  2004-04-14       Impact factor: 4.030

7.  Nicotine self-administration in rats on a progressive ratio schedule of reinforcement.

Authors:  E C Donny; A R Caggiula; M M Mielke; S Booth; M A Gharib; A Hoffman; V Maldovan; C Shupenko; S E McCallum
Journal:  Psychopharmacology (Berl)       Date:  1999-11       Impact factor: 4.530

Review 8.  Hypothalamic dopamine and serotonin in the regulation of food intake.

Authors:  M M Meguid; S O Fetissov; M Varma; T Sato; L Zhang; A Laviano; F Rossi-Fanelli
Journal:  Nutrition       Date:  2000-10       Impact factor: 4.008

Review 9.  Synaptic plasticity and nicotine addiction.

Authors:  J A Dani; D Ji; F M Zhou
Journal:  Neuron       Date:  2001-08-16       Impact factor: 17.173

10.  Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers.

Authors:  Deon M Harvey; Sevil Yasar; Stephen J Heishman; Leigh V Panlilio; Jack E Henningfield; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2004-03-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.